Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011;364:146–56.
Article
PubMed
PubMed Central
CAS
Google Scholar
Lakhanpal V, Schocket SS, Jiji R. Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology. 1984;91:443–51.
Article
PubMed
CAS
Google Scholar
Haimovici R, D’Amico DJ, Gragoudas ES, Sokol S. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology. 2002;109:164–71.
Article
PubMed
Google Scholar
Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M. ISCEV standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol. 2009;118:69–77.
Article
PubMed
CAS
Google Scholar
Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033–48.
Article
PubMed
CAS
Google Scholar
Taher A, Bashshur Z, Shamseddeen WA, Abdulnour RE, Aoun E, Koussa S, Baz P. Ocular findings among thalassemia patients. Am J Ophthalmol. 2006;142:704–5.
Article
PubMed
Google Scholar
Taneja R, Malik P, Sharma M, Agarwal MC. Multiple transfused thalassemia major: ocular manifestations in a hospital-based population. Indian J Ophthalmol. 2010;58:125–30.
Article
PubMed
PubMed Central
Google Scholar
De Virgiliis S, Congia M, Turco MP, Frau F, Dessi C, Argiolu F, Sorcinelli R, Sitzia A, Cao A. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. Arch Dis Child. 1988;63(3):250–5.
Article
PubMed
PubMed Central
CAS
Google Scholar
Arora A, Wren S, Gregory Evans K. Desferrioxamine related maculopathy: a case report. Am J Hematol. 2004;76:386–8.
Article
PubMed
Google Scholar
Aessopos A, Savvides P, Stamatelos G, et al. Pseudoxanthoma elasticum-like skin lesions and angioid streaks in beta-thalassemia. Am J Hematol. 1992;41:159–64.
Article
PubMed
CAS
Google Scholar
Barteselli G, Dell'arti L, Finger RP, Charbel Issa P, Marcon A, Vezzola D, Mapelli C, Cassinerio E, Cappellini MD, Ratiglia R, Viola F. The spectrum of ocular alterations in patients with beta-thalassemia syndromes suggests a pathology similar to pseudoxanthoma elasticum. Ophthalmology. 2014;121:709–18.
Article
PubMed
Google Scholar
Aessopos A, Voskaridou E, Kavouklis E, Vassilopoulos G, Rombos Y, Gavriel L, Loukopoulos D. Angioid streaks in sickle-thalassemia. Am J Ophthalmol. 1994;117:589–92.
Article
PubMed
CAS
Google Scholar
Fanny A, Coulibaly F, Gbe K, Meite M, Adjorlolo C, Konan-Toure ML, Berete R, Boni S, Ouattara A, Diallo M. Sickle cell beta-thalassemia leading to serious ischemic retinopathy: a study of 18 patients in Abidjan. J Fr Ophtalmol. 2005;28:391–5.
Article
PubMed
CAS
Google Scholar
Bonkovsky HL, Davidoff A, Stark DD. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343:1656. author reply 1657.
Hadziahmetovic M, Pajic M, Grieco S, Song Y, Song D, Li Y, Cwanger A, Iacovelli J, Chu S, Ying G, Connelly J, Spino M, Dunaief J. The oral Iron Chelator Deferiprone protects against retinal degeneration induced through diverse mechanisms. Transl Vis Sci Technol. 2012;1:7.
Article
PubMed
PubMed Central
Google Scholar
Song D, Song Y, Hadziahmetovic M, Zhong Y, Dunaief JL. Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retina. Free Radic Biol Med. 2012;53:64–71.
Article
PubMed
PubMed Central
CAS
Google Scholar
Song D, Zhao L, Li Y, Hadziahmetovic M, Song Y, Connelly J, Spino M, Dunaief JL. The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice. Invest Ophthalmol Vis Sci. 2014;55:4525–32.
Article
PubMed
PubMed Central
CAS
Google Scholar
Pan Y, Keane PA, Sadun AA, Fawzi AA. Optical coherence tomography findings in deferasirox-related maculopathy. Retin Cases Brief Rep. 2010;4:229–32.
Article
PubMed
Google Scholar
Walia HS, Yan J. Reversible retinopathy associated with oral deferasirox therapy. BMJ Case Rep. 2013; 2013. pii: bcr2013009205.
Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet. 1983;2:181–4.
Article
PubMed
CAS
Google Scholar
Cohen A, Martin M, Mizanin J, et al. Vision and hearing during deferoxamine therapy. J Pediatr. 1990;117:326–30.
Article
PubMed
CAS
Google Scholar
Baath JS, Lam WC, Kirby M, Chun A. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population. Retina. 2008;28:894–9.
Article
PubMed
Google Scholar
Viola F, Barteselli G, Dell'arti L, Vezzola D, Villani E, Mapelli C, Zanaboni L, Cappellini MD, Ratiglia R. Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine. Ophthalmology. 2012;119:1693–700.
Article
PubMed
Google Scholar
Viola F, Barteselli G, DellʼArti L, Vezzola D, Mapelli C, Villani E, Ratiglia R. Multimodal imaging in deferoxamine retinopathy. Retina. 2014;34:1428–38.
Article
PubMed
Google Scholar
Gonzales CR, Lin AP, Engstrom RF, Kreiger AE. Bilateral vitelliform maculopathy and deferoxamine toxicity. Retina. 2004;24:464–7.
Article
PubMed
Google Scholar
Genead MA, Fishman GA, Anastasakis A, Lindeman M. Macular vitelliform lesion in desferrioxamine-related retinopathy. Doc Ophthalmol. 2010;121:161–6.
Article
PubMed
PubMed Central
Google Scholar
Rahi AH, Hungerford JL, Ahmed AI. Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. Br J Ophthalmol. 1986;70:373–81.
Article
PubMed
PubMed Central
CAS
Google Scholar
Reddy S, Iturralde D, Meyerle C, Gross NE, Yannuzzi LA. Fundus autofluorescence in retinopathy caused by deferoxamine toxicity. Retin Cases Brief Rep. 2007;1:120–2.
Article
PubMed
Google Scholar
Pall H, Blake DR, Winyard P, Lunec J, Williams A, Good PA, Kritzinger EE, Cornish A, Hider RC. Ocular toxicity of desferrioxamine-an example of copper promoted auto-oxidative damage? Br J Ophthalmol. 1989;73:42–7.
Article
PubMed
PubMed Central
CAS
Google Scholar
Chaston TB, Richardson DR. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol. 2003;73:200–10.
Article
PubMed
CAS
Google Scholar
Klettner A, Koinzer S, Waetzig V, Herdegen T, Roider J. Deferoxamine mesylate is toxic for retinal pigment epithelium cells in vitro, and its toxicity is mediated by p38. Cutan Ocul Toxicol. 2010;29:122–9.
Article
PubMed
CAS
Google Scholar
Dettoraki M, Kattamis A, Ladas I, Maragkos K, Koutsandrea C, Chatzistefanou K, Laios K, Brouzas D, Moschos MM. Electrophysiological assessment for early detection of retinal dysfunction in β-thalassemia major patients. Graefes Arch Clin Exp Ophthalmol. 2017;255:1349–58.
Article
PubMed
CAS
Google Scholar
Arden GB, Wonke B, Kennedy C, Huehns ER. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol. 1984;68:873–7.
Article
PubMed
PubMed Central
CAS
Google Scholar
Jiang C, Hansen RM, Gee BE, Kurth SS, Fulton AB. Rod and rod mediated function in patients with beta-thalassemia major. Doc Ophthalmol. 1999;96:333–45.
Article
CAS
Google Scholar
Bui KM, Sadda SR, Salehi-Had H. Pseudovitelliform maculopathy associated with deferoxamine toxicity: multimodal imaging and electrophysiology of a rare entity. Digit J Ophthalmol. 2017;23:11–5.
Article
PubMed
PubMed Central
Google Scholar
Roulez F. Retinal pigment epithelium-desferal. Bull Soc Belge Ophtalmol. 2007;304:59–66.
Google Scholar
Kertes PJ, Lee TK, Coupland SG. The utility of multifocal electroretinography in monitoring drug toxicity: deferoxamine retinopathy. Can J Ophthalmol. 2004;39:656–61.
Article
PubMed
Google Scholar
Genead MA, Fishman GA. Efficacy of brinzolamide ophthalmic suspension 1% for treatment of a vitelliform macular lesion in a patient with desferrioxamine retinopathy. Ophthalmic Surg Lasers Imaging 2011;42:e114–e117.Online.